TRASTUZUMAB DUOCARMAZINE FOR DUMMIES

Among the most below-investigated “driving forces” involved with trastuzumab resistance is PTEN. Nagata et al. (2004) noted which the lack of PTEN was observed in 36% of HER2-beneficial Major breast tumor specimens from patients with stage IV disorder. Furthermore, In addition they showed that individuals with PTEN-deficient tumors experienced